dc.contributor.author | Vidal, Silvia | |
dc.contributor.author | Puig, Lluís | |
dc.contributor.author | Carrascosa-Carrillo, José-Manuel | |
dc.contributor.author | González-Cantero, Álvaro | |
dc.contributor.author | Ruiz-Carrascosa, José-Carlos | |
dc.contributor.author | Velasco-Pastor, Antonio-Manuel | |
dc.date.accessioned | 2021-11-04T11:01:35Z | |
dc.date.available | 2021-11-04T11:01:35Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1661-6596 | spa |
dc.identifier.uri | http://hdl.handle.net/10641/2577 | |
dc.description.abstract | The paradigm of psoriasis as a Th17-driven disease has evolved in the last years towards a
much deeper knowledge of the complex pathways, mechanisms, cells, and messengers involved,
highlighting the crucial role played by the IL-17 family of cytokines. All IL-17 isoforms signal through
IL-17R. Five subunits of IL-17R have been described to date, which couple to form a homo- or heteroreceptor
complex. Characteristically, IL-17RA is a common subunit in all hetero-receptors. IL-17RA
has unique structural—containing a SEFIR/TILL domain—and functional—requiring ACT-1 for
signaling—properties, enabling Th17 cells to act as a bridge between innate and adaptive immune
cells. In psoriasis, IL-17RA plays a key role in pathogenesis based on: (a) IL-17A, IL-17F, and other
IL-17 isoforms are involved in disease development; and (b) IL-17RA is essential for signaling of
all IL-17 cytokines but IL-17D, whose receptor has not been identified to date. This article reviews
current evidence on the biology and role of the IL-17 family of cytokines and receptors, with focus on
IL-17RA, in psoriasis and some related comorbidities, and puts them in context with current and
upcoming treatments. | spa |
dc.language.iso | eng | spa |
dc.publisher | International Journal of Molecular Sciences | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | psoriasis | spa |
dc.subject | Th17 | spa |
dc.subject | IL-17 | spa |
dc.subject | IL-17R | spa |
dc.subject | monoclonal antibodies | spa |
dc.subject | secukinumab | spa |
dc.subject | ixekizumab | spa |
dc.subject | bimekizumab | spa |
dc.subject | brodalumab | spa |
dc.title | From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 1.096 KB | spa |
dc.identifier.doi | 10.3390/ijms22136740 | spa |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/22/13/6740 | spa |